“`html
Gene Solutions and Dingjing Bio Partner to Expand Cancer Screening Access in China
China. Innovative oncology solutions and a vast hospital network aim to improve early detection and treatment."/>
Shanghai, China – In a move set to revolutionize cancer detection and management, Asia’s leading biotech firm, Gene Solutions, has announced a strategic collaboration with Zhejiang Shaoxing Dingjing Biomedical Technology Co., Ltd. (Dingjing Bio). The partnership,revealed on June 12,2025,aims to integrate Gene Solutions’ cutting-edge oncology solutions with Dingjing Bio’s extensive network of over 1,300 hospitals across China,enhancing early cancer screening and monitoring nationwide.
Strategic Alliance for Enhanced Cancer Detection
Dingjing Bio, a prominent CAP-certified laboratory in China, operates a extensive next-generation sequencing (NGS) platform.This collaboration will leverage Gene Solutions’ innovative products to bolster Dingjing Bio’s medical capabilities in oncology. The collaboration focuses on clinical verification, translational research, and joint commercialization, with the goal of improving treatment outcomes and health management for cancer patients in the region.
Did You Know? Early cancer detection significantly improves treatment outcomes. According to the American Cancer Society, the 5-year survival rate for many cancers is much higher when the disease is found early and hasn’t spread [2].
Key oncology Solutions to be Introduced:
- Spot-mas: Asia’s first clinically validated multi-cancer early screening (MCED) blood test, enabling early detection of various cancers through a single blood draw.
- Spot-mas lung: A specialized testing scheme designed for the early screening of lung cancer.
- K-4CARE: An integrated platform for genome and transcriptome analysis, utilizing ctDNA-based micro-residual lesions (MRD) monitoring technology to support personalized therapeutic strategies and long-term disease management.
These advanced tools will enrich Dingjing Bio’s existing tumor detection product line, providing hospitals with state-of-the-art resources for cancer screening and management.
Executive Perspectives on the Collaboration
Chen Weiqiang, chairman of Dingjing Bio, emphasized the strategic value of the partnership, stating, “This cooperation with gene Solutions is not only expected to enhance our technical capabilities in the field of oncology detection, but also has far-reaching strategic value. The two parties can jointly promote the localization and transformation of new technologies and the transformation of results.”
Dr. Nguyen hoai Nghia, Co-founder and CEO of Gene Solutions, added, “We are driving this in China with a strong infrastructure and hospital coverage network. [Dingjing Bio is an] ideal partner for oncology applications. We will work together to effectively integrate cutting-edge cancer genomics technologies into the clinical diagnosis and treatment system, benefiting a wider patient population.”
Dingjing Bio: A Leader in oncology Solutions
Headquartered in Shaoxing, Zhejiang, with R&D in Shanghai and production in Anhui, Dingjing Bio is a leading provider of comprehensive oncology solutions in China. The company’s business spans 30 provinces, cities, and autonomous regions, serving over 1,300 cooperative hospitals and more than 100,000 patients. Dingjing Bio integrates various technical platforms, including qPCR, NGS, dPCR, and flow cytometry, for applications in early cancer screening, diagnosis, and disease monitoring.
Pro Tip: Regular cancer screenings are crucial for early detection. Consult with your healthcare provider to determine the appropriate screening schedule based on your age, family history, and risk factors.
The company operates 13 holding subsidiaries, 3 medical laboratories, and 43 hospital-based medical laboratories. Dingjing Bio has received numerous certifications, including CAP accreditation and domestic clinical gene amplification laboratory certification.
Gene Solutions: Pioneering Cancer Treatment Innovations
Gene Solutions, a multinational biotech company based in Asia, is renowned for its innovative approach to cancer treatment. By combining artificial intelligence with circulating tumor DNA (ctDNA) technology, the company delivers comprehensive solutions for the entire cancer treatment process. Gene Solutions’ proprietary research and CAP-certified laboratories drive the growth of advanced oncology diagnostics and personalized treatment models.
With a strong regional presence and a commitment to improving medical accessibility, Gene Solutions is transforming cancer diagnosis and personalized treatment in the Asia-Pacific region.
Key Metrics of the Partnership
| Metric | Description |
|---|---|
| Hospitals Covered | Over 1,300 hospitals across China |
| Geographic Reach | 30 provinces, cities, and autonomous regions |
| Patients Served | Over 100,000 patients |
| key Technologies | qPCR, NGS, dPCR, flow cytometry, ctDNA analysis |
The Growing Need for Cancer screening
Cancer remains a leading cause of death worldwide, but early detection can significantly improve survival rates [1]. Advances in genomic technologies and personalized medicine are paving the way for more effective cancer screening and treatment strategies. Partnerships like the one between Gene Solutions and Dingjing Bio are crucial for expanding access to these innovations and improving patient outcomes.
The global cancer burden is expected to increase in the coming decades, driven by factors such as aging populations and lifestyle changes. According to the World Health Organization, there were an estimated 20 million new cancer cases and 10 million cancer deaths in 2020. Early detection and access to quality treatment are essential for reducing the impact of this disease.
Frequently Asked questions About Cancer screening
What is cancer?
Cancer is a group of diseases characterized by the uncontrolled growth and spread of abnormal cells. These cells can invade and destroy healthy tissues, leading to various health problems [3].
how does early cancer screening help?
Early cancer screening can detect cancer at an early stage, when it is more likely to be treated successfully. Screening tests can identify abnormalities before symptoms appear, allowing for timely intervention and improved outcomes.
What are the different types of cancer screening tests?
There are various types of cancer screening tests, including blood tests, imaging tests (such as mammograms and CT scans), and endoscopic procedures (such as colonoscopies). The appropriate screening tests depend on the type of cancer and individual risk factors.
Disclaimer: This article provides details for general knowledge and awareness only. It does not constitute medical advice. Consult with a qualified healthcare professional for any health concerns or before making any decisions related to your health or treatment.
What are your thoughts on the role of technology in early cancer detection? How can we make cancer screening more accessible to everyone?
<
